JPWO2020122034A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020122034A5 JPWO2020122034A5 JP2020560106A JP2020560106A JPWO2020122034A5 JP WO2020122034 A5 JPWO2020122034 A5 JP WO2020122034A5 JP 2020560106 A JP2020560106 A JP 2020560106A JP 2020560106 A JP2020560106 A JP 2020560106A JP WO2020122034 A5 JPWO2020122034 A5 JP WO2020122034A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- amino acid
- seq
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024221344A JP2025041725A (ja) | 2018-12-11 | 2024-12-18 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018231948 | 2018-12-11 | ||
| JP2018231948 | 2018-12-11 | ||
| PCT/JP2019/048171 WO2020122034A1 (ja) | 2018-12-11 | 2019-12-10 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024221344A Division JP2025041725A (ja) | 2018-12-11 | 2024-12-18 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020122034A1 JPWO2020122034A1 (ja) | 2021-10-28 |
| JPWO2020122034A5 true JPWO2020122034A5 (enExample) | 2022-12-14 |
| JP7608164B2 JP7608164B2 (ja) | 2025-01-06 |
Family
ID=71076370
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560106A Active JP7608164B2 (ja) | 2018-12-11 | 2019-12-10 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
| JP2024221344A Pending JP2025041725A (ja) | 2018-12-11 | 2024-12-18 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024221344A Pending JP2025041725A (ja) | 2018-12-11 | 2024-12-18 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220023436A1 (enExample) |
| EP (1) | EP3909580A4 (enExample) |
| JP (2) | JP7608164B2 (enExample) |
| KR (1) | KR102905497B1 (enExample) |
| CN (1) | CN113271942A (enExample) |
| AU (1) | AU2019396895B2 (enExample) |
| BR (1) | BR112021011119A2 (enExample) |
| EA (1) | EA202191641A1 (enExample) |
| SG (1) | SG11202106248XA (enExample) |
| WO (1) | WO2020122034A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019396895B2 (en) * | 2018-12-11 | 2025-09-11 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with PARP inhibitor |
| IL288485B2 (en) * | 2019-05-29 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-TROP2 antibody conjugates - a drug for use in cancer treatment |
| IL301921A (en) * | 2020-10-09 | 2023-06-01 | Daiichi Sankyo Co Ltd | Combining an antibody-drug conjugate and a selective 1PARP inhibitor |
| WO2022248268A1 (en) * | 2021-05-28 | 2022-12-01 | Adc Therapeutics Sa | Combination therapy |
| CA3224492A1 (en) | 2021-07-19 | 2023-01-26 | Xiaojun Han | Immunoconjugates and methods |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| AU2022392822B9 (en) * | 2021-11-18 | 2026-08-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| CN116407612A (zh) * | 2021-12-29 | 2023-07-11 | 上海市第十人民医院 | 一种药物组合物及其在制备抗肿瘤药物中的应用 |
| CA3248038A1 (en) * | 2022-04-12 | 2023-10-19 | Minerva Biotechnologies Corporation | ANTI-MUC1* VARIABLE ANTIBODIES AND RELATED USES |
| CN119255825A (zh) * | 2022-05-24 | 2025-01-03 | 第一三共株式会社 | 抗-cdh6抗体-药物缀合物的剂量方案 |
| AU2024236246A1 (en) * | 2023-03-14 | 2025-10-30 | Daiichi Sankyo Company, Limited | Combination of anti-CDH6 antibody-drug conjugate and VEGF inhibitor |
| JPWO2024204679A1 (enExample) * | 2023-03-31 | 2024-10-03 | ||
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| EP4495003A1 (en) | 2023-07-20 | 2025-01-22 | AIRBUS HELICOPTERS DEUTSCHLAND GmbH | An external cargo adapter for use with a rotorcraft |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026019375A1 (en) * | 2024-07-19 | 2026-01-22 | Hummingbird Bioscience Pte. Ltd. | B7h3-binding molecules |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026133218A1 (en) | 2024-12-20 | 2026-06-25 | Astrazeneca Uk Limited | Combination of anti-her2 antibody-drug conjugate and anti-trop2 antibody-drug conjugate |
| WO2026158602A1 (zh) * | 2025-01-23 | 2026-07-30 | 康百达（四川）生物医药科技有限公司 | Parp1抑制剂联合adc的药物组合及其治疗肿瘤的用途 |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| AR024464A1 (es) | 1999-06-25 | 2002-10-02 | Genentech Inc | Anticuerpos anti-erbb2 humanizados. |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| NZ579644A (en) | 2007-02-16 | 2012-05-25 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| JP6282232B2 (ja) | 2012-02-10 | 2018-02-21 | ユニバーシティー オブ メリーランド，ボルティモア | 抗体及びそのＦｃフラグメントの酵素化学的糖鎖改変 |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| EP2910573B1 (en) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| SG10201902571VA (en) * | 2013-12-25 | 2019-04-29 | Daiichi Sankyo Co Ltd | Anti-trop2 antibody-drug conjugate |
| SG11201603960XA (en) * | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| US11185594B2 (en) | 2014-04-10 | 2021-11-30 | Daiichi Sankyo Company, Limited | (Anti-HER2 antibody)-drug conjugate |
| TWI871999B (zh) | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| US10195175B2 (en) * | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| CA2990572C (en) | 2015-06-29 | 2022-07-26 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| SG11201906554RA (en) * | 2017-01-17 | 2019-08-27 | Daiichi Sankyo Co Ltd | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
| TWI926682B (zh) | 2017-05-15 | 2026-05-21 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製造方法 |
| EP3677589B1 (en) | 2017-08-31 | 2025-11-26 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| AU2019396895B2 (en) * | 2018-12-11 | 2025-09-11 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with PARP inhibitor |
-
2019
- 2019-12-10 AU AU2019396895A patent/AU2019396895B2/en active Active
- 2019-12-10 JP JP2020560106A patent/JP7608164B2/ja active Active
- 2019-12-10 CN CN201980082698.7A patent/CN113271942A/zh active Pending
- 2019-12-10 EP EP19895941.3A patent/EP3909580A4/en active Pending
- 2019-12-10 SG SG11202106248XA patent/SG11202106248XA/en unknown
- 2019-12-10 WO PCT/JP2019/048171 patent/WO2020122034A1/ja not_active Ceased
- 2019-12-10 US US17/312,084 patent/US20220023436A1/en active Pending
- 2019-12-10 EA EA202191641A patent/EA202191641A1/ru unknown
- 2019-12-10 KR KR1020217021368A patent/KR102905497B1/ko active Active
- 2019-12-10 BR BR112021011119A patent/BR112021011119A2/pt unknown
-
2024
- 2024-12-18 JP JP2024221344A patent/JP2025041725A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025041725A5 (enExample) | ||
| JP2023539715A5 (enExample) | ||
| JP2023542066A5 (enExample) | ||
| JPWO2020031936A5 (enExample) | ||
| JP2023545096A5 (enExample) | ||
| JP2023070678A5 (enExample) | ||
| JPWO2020130125A5 (enExample) | ||
| JPWO2020022475A5 (enExample) | ||
| JP2019031565A5 (enExample) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2025041725A (ja) | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ | |
| JP2020509027A5 (enExample) | ||
| JP2020515578A5 (enExample) | ||
| JPWO2020059772A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| JP2015528818A5 (enExample) | ||
| JP2012522512A5 (enExample) | ||
| JP2012522513A5 (enExample) | ||
| HRP20171789T1 (hr) | Konjugati humanog protutijela s lijekom protiv tkivnog faktora | |
| JP2018525354A5 (enExample) | ||
| JP2015527318A5 (enExample) | ||
| JP2021527640A5 (enExample) | ||
| TWI838358B (zh) | 疏水性奧瑞他汀(auristatin)f化合物及其結合物 | |
| JPWO2022102695A5 (enExample) | ||
| JP2020526584A5 (enExample) |